Chiesi Farmaceutici S.p.A.
Stories
-
Chiesi registers Phase 3 trial of CHF5993 vs Seretide in adolescent asthma
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 700 participants and start on November 16, 2026. It compares CHF5993 100/6/12.5 μg pMDI to Seretide Evohaler 125/25 μg pMDI over 52 weeks in adolescents with uncontrolled asthma.